Skip to main content
. Author manuscript; available in PMC: 2024 Sep 24.
Published in final edited form as: Vaccine. 2024 Feb 22;42(8):2018–2025. doi: 10.1016/j.vaccine.2024.02.010

Table 3.

In participants who made as per protocol visits, Geometric mean fold rise(95% CI) and seroconversion of IgG and IgA in 9-month and 12-month groups.

9-month 12-month
Visit 1–2 Visit 1–3 Visit 3–4 Visit 1–4 Visit 1–2 Visit 1–3 Visit 3–4 Visit 1–4
IgG
Geometric mean fold rise (95 % CI) 1087.12
(616.49–1557.75)		 87.90
(64.19–111.61)		 10.03
(5.99–14.07)		 684.72
(420.19to
949.24)		 713.43
(544.21–882.65)		 309.10
(186.41 to 431.79)		 1.15
(0.73–1.57)		 309.10
(186.41–431.79)
4-fold increase (%) 27/27 (100 %) 32/32 (100 %) 16/20 (80 %) 20/20 (100 %) 32/32 (100 %) 16/16 (100 %) 0/8 (0 %) 10/10 (100 %)
IgA
Geometric mean fold rise (95 % CI) 51.57 (18.02
85.13)		 9.59
(5.52–13.66)		 4.26
(2.77–5.75)		 21.41
(13.47–29.34)		 100.61
(–26.20–227.43)		 22.36
(11.46–33.26)		 0.97 (0.65 
to1.29)		 22.83
(8.04–37.62)
4-fold increase
(%)		 27/27 (100 %) 24/32 (75 %) 9/20 (45 %) 20/20 (100 %) 31/32 (96.88 %) 14/16 (87.5 %) 0/8 (0 %) 8/10 (80 %)